



25 March 2021

EnGeneIC Announces Board Appointment - Professor Bryan Williams

EnGeneIC is pleased to announce the appointment of Professor Bryan Williams to the Board of EnGeneIC Limited.

Bryan is an internationally recognized cancer researcher and research administrator, with significant business and Board experience in the Biotechnology sector.

Bryan is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne. Bryan was previously a Director of Cancer Trials Australia, Director of the Monash Institute of Medical Research, and Director and CEO of the Hudson Institute of Medical Research.

Bryan received his PhD from the University of Otago, New Zealand and completed postdoctoral training at the National Institute for Medical Research in London. Bryan has held faculty positions at the University of Toronto and the Hospital for Sick Children, Toronto, Canada. He was Chairman of the Department of Cancer Biology at the Lerner Research Institute, Cleveland Clinic, USA.

In addition to his cancer research activities, Bryan holds Board and advisory positions with several Biotechnology companies and Research Trusts.

Bryan has been a Director since 2013 and is currently Deputy Chairman of Pacific Edge Limited, a cancer diagnostic company listed on the stock exchange in New Zealand and between 2006 and 2013 he was Chairman and Audit Committee Member of the NASDAQ listed biopharma company MEI Pharma, Inc.

Among other board, trust and advisory activities, he is currently a member of the Board of Trustees of the Hope Funds For Cancer Research based in the USA.

Bryan is well known to EnGeneIC and has been one of our scientific advisors since 2016.

As you are aware, we are refreshing EnGeneIC's Board and Bryan will add significant value, drawing on his extensive experience and expertise in oncology and immune system activation as well as his business knowledge and understanding of publicly listed company governance processes particularly his NASDAQ experience as we head towards a possible listing in 2022.